Exploration of a new therapy for lung cancer

Non-small cell lung cancer (NSCLC) is an inherently insensetive tumor to many types of treatment. In early stages of disease it is treated by surgery. When sugery is not possible, radiation is the standard treatment for locally inoperable NSCLC. In recent years combination treatments of radiation chemotherapy have been used to improve survival in locally inoperable NSCLC. Several randomized studies in this group of patients show, indeed, doubling of the 2-year survival. ... Zie: Summary and concusions

Внутренние источники финансирования инвестиционной деятельности в Украине

В статье рассмотрены 4 основных источника финансирования инвестиционной деятельности, и проблемы связанные с их формированием и использованием. Учитывая непосредственное влияние внутренних источников инвестиций на экономический рост, и их минимальное использование в Украине, тема становится актуальной, требующей детальной проработки.У статті розглянуті 4 основні джерела фінансування інвестиційної діяльності та проблеми, пов'язані з їх формуванням та використанням. З огляду на безпосередній вплив внутрішніх джерел інвестицій на економічний зріст, та їх мінімальне використання в Україні, тема стає актуальною, потребуючою детального опрацювання.Four basic sources of financing investment activity as well as problems related to their forming and use are considered in the article. This theme is essential and needs detailed development under circumstances of direct impact of the internal sources of investment on economical growth and still minimum use in Ukraine

Early lung cancer detection by low-dose CT screening: Therapeutic implications

Introduction: Lung cancer screening by low-dose chest computed tomography is currently implemented in the U.S. After implementation of screening, a stage shift may be observed from around 15% stage I non-small cell lung cancers (NSCLCs) in routine clinical practice to up to 70% in screening patients. This indicates a move in treatment options from advanced to early lung cancers, especially in those with small suspected intrapulmonary nodules. Areas covered: We have reviewed the current status of lung cancer screening from the different randomized controlled lung cancer screening studies and the clinical evidence so far for both surgical and non-surgical treatment options for (screen-detected) stage I NSCLC. Furthermore, we provide a step-wise approach for the treatment of stage I NSCLC. Expert Commentary: Recommended treatment for stage I NSCLC remains (VATS) lobectomy in case of a medically operable patient, VATS sublobar resection for subcentimeter nodules, and SBRT otherwise. Currently, there is too limited evidence for the value of ablative techniques in curative treatment of early stage NSCLC. Therefore, these therapies should only be used in expert centers for selected patients in clinical studies

Nieuwe 'doelgerichte behandeling' van longkanker

Patients with non-small cell lung cancer with specific mutations for which so-called 'targeted therapy' is available are likely to have a favourable tumour response. The first patient, a man aged 64 with an activating epidermal growth factor receptor (EGFR) mutation, had a longstanding tumour response on erlotinib, an EGFR tyrosine kinase inhibitor (TKI). After 16 months on treatment, there was still no progression of the disease. The next patient, a woman aged 78, also responded favourably to erlotinib After 2.5 years she discontinued the medication and the disease recurred. Remission was induced again with the use of erlotinib, but the recovery was of short duration and she died a few months later. A third patient, a 66-year-old man, developed resistance to erlotinib due to a T790M mutation in the EGFR protein. He responded well to a combination of the irreversible EGFR-TKI afatinib and the antibody to EGFR, cetuximab. The final patient, a 47-year-old woman, had an EML4-ALK translocation and responded remarkably well to an ALK inhibitor, crozotinib. Mutation analysis should be carried out in all patients with metastatic adenocarcinoma or large cell lung cancer, specifically for genes for which a targeted therapy is already available

New 'targeted therapy' for lung cancer

Patients with non-small cell lung cancer with specific mutations for which so-called 'targeted therapy' is available are likely to have a favourable tumour response. The first patient, a man aged 64 with an activating epidermal growth factor receptor (EGFR) mutation, had a longstanding tumour response on erlotinib, an EGFR tyrosine kinase inhibitor (TKI). After 16 months on treatment, there was still no progression of the disease. The next patient, a woman aged 78, also responded favourably to erlotinib After 2.5 years she discontinued the medication and the disease recurred. Remission was induced again with the use of erlotinib, but the recovery was of short duration and she died a few months later. A third patient, a 66-year-old man, developed resistance to erlotinib due to a T790M mutation in the EGFR protein. He responded well to a combination of the irreversible EGFR-TKI afatinib and the antibody to EGFR, cetuximab. The final patient, a 47-year-old woman, had an EML4-ALK translocation and responded remarkably well to an ALK inhibitor, crozotinib. Mutation analysis should be carried out in all patients with metastatic adenocarcinoma or large cell lung cancer, specifically for genes for which a targeted therapy is already available.</p